Related Experiment Video
Updated: Dec 13, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes
Erica P Cai1, Yuki Ishikawa2, Wei Zhang2
1Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
Abstract:
Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells. Pluripotent stem cells can now be differentiated into beta cells, thus raising the prospect of a cell replacement therapy for T1D. However, autoimmunity would rapidly destroy newly transplanted beta cells. Using a genome-scale CRISPR screen in a mouse model for T1D, we show that deleting RNLS, a genome-wide association study candidate gene for T1D, made beta cells resistant to autoimmune killing. Structure-based modelling identified the U.S. Food and Drug Administration-approved drug pargyline as a potential RNLS inhibitor. Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal. Furthermore, pargyline prevented or delayed diabetes onset in several mouse models for T1D. Our results identify RNLS as a modifier of beta cell vulnerability and as a potential therapeutic target to avert beta cell loss in T1D.
Insights
Researchers found a way to protect transplanted beta cells in type 1 diabetes (T1D) by targeting the RNLS gene. Inhibiting RNLS with the drug pargyline reversed diabetes in mice, offering a new therapeutic strategy.
Area of Science:
- Immunology
- Genetics
- Pharmacology
Background:
- Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells.
- Stem cell-derived beta cells offer potential for T1D cell replacement therapy.
- Transplanted beta cells are vulnerable to rapid autoimmune attack.
Purpose of the Study:
- To identify genetic targets that confer resistance to autoimmune destruction in beta cells.
- To explore therapeutic strategies for protecting beta cells in T1D.
Main Methods:
- Genome-scale CRISPR screening in a mouse model of T1D.
- Structure-based modeling to identify potential RNLS inhibitors.
- Treatment with pargyline in mouse models of T1D.
Main Results:
- Deletion of RNLS, a T1D GWAS candidate gene, rendered beta cells resistant to autoimmune killing.
- Pargyline, an RNLS inhibitor, protected transplanted beta cells and reversed diabetes in mice.
- Pargyline administration prevented or delayed diabetes onset in multiple T1D mouse models.
Conclusions:
- RNLS is a key modifier of beta cell vulnerability in T1D.
- RNLS inhibition represents a promising therapeutic target to prevent beta cell loss and treat T1D.
